Oncolytics Biotech (TSE:ONC) Stock Price Down 1.3% – Here’s Why
by Sarita Garza · The Markets DailyOncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares traded down 1.3% during trading on Thursday. The stock traded as low as C$14.90 and last traded at C$14.90. Approximately 280 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 169,589 shares. The stock had previously closed at C$15.10.
Oncolytics Biotech Stock Down 1.3%
The stock has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a current ratio of 2.82, a quick ratio of 8.86 and a debt-to-equity ratio of 17.78. The firm’s fifty day moving average is C$14.90 and its 200 day moving average is C$14.90.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.